Priscoline hydrochloride injection®
Priscoline hydrochloride, tolazoline hydrochloride injection, USP, is a peripheral vasodilator available in ampuls for intravenous administration.
Priscoline is indicated for the treatment of persistent pulmonary hypertension of the newborn (“persistent fetal circulation”) when systemic arterial oxygenation cannot be satisfactorily maintained by usual supportive care (supplemental oxygen and/or mechanical ventilation).
Priscoline should be used in a highly supervised setting, where vital signs, oxygenation, acid-base status, fluid, and electrolytes can be monitored and maintained.
Media Articles Related to Priscoline (Tolazoline)
Genetically-modified probiotic may one day treat pulmonary hypertension
Source: Cardiovascular / Cardiology News From Medical News Today [2016.09.15]
An oral, genetically-modified strain of the probiotic Lactobacillus was used to treat rats with high blood pressure in the lungs, which resulted in reduced blood pressure, improved heart...
New understanding of pulmonary hypertension leads to promising drug targets
Source: Hypertension News From Medical News Today [2016.08.22]
A groundbreaking new study led by researchers from the University of Pittsburgh and UPMC has identified a new group of compounds that could have robust effects in treating pulmonary hypertension...
Published Studies Related to Priscoline (Tolazoline)
Antagonism of detomidine sedation in the horse using intravenous tolazoline or atipamezole. [2006.05]
REASONS FOR PERFORMING STUDY: The ability to shorten the duration of sedation would potentially improve safety and utility of detomidine...
A novel approach for percutaneous treatment of massive nonocclusive mesenteric ischemia: tolazoline and glycerol trinitrate as effective local vasodilators. [2009.02.01]
Nonocclusive mesenteric ischemia (NOMI) generally affects patients with low cardiac output, resulting in splanchnic hypoperfusion. It includes all forms of mesenteric ischemia without vessel occlusion and makes up between 20 and 30% of all cases of acute mesenteric ischemia... Although LIVT was complicated by severe cardiovascular complications inclusive of cardiac arrest with the need of cardiopulmonary resuscitation, the patient fully recovered and was discharged after implantation of a cardiac pacemaker in good clinical condition 7 days later.
A comparison of two combinations of xylazine-ketamine administered intramuscularly to alpacas and of reversal with tolazoline. [2008.05]
OBJECTIVE: To evaluate the anesthetic and cardiorespiratory effects of two doses of intramuscular (IM) xylazine/ketamine in alpacas, and to determine if tolazoline would reduce the anesthetic recovery time. STUDY DESIGN: Prospective randomized crossover study. ANIMALS: Six castrated male alpacas... CONCLUSIONS: The HD provided more consistent clinical effects in alpacas than the LD. Intramuscular tolazoline shortened the duration of lateral recumbency in alpacas anesthetized with the HD combination. CLINICAL RELEVANCE: Both doses of the combination were effective in providing restraint in alpacas and the duration of restraint was dose dependent. Supplemental oxygen should be available if using the HD and IM administration of tolazoline will shorten the recovery time.
A comparison of two combinations of xylazine-ketamine administered intramuscularly to alpacas and of reversal with tolazoline. [2008.02.18]
Objective To evaluate the anesthetic and cardiorespiratory effects of two doses of intramuscular (IM) xylazine/ketamine in alpacas, and to determine if tolazoline would reduce the anesthetic recovery time... Supplemental oxygen should be available if using the HD and IM administration of tolazoline will shorten the recovery time.
Clinical Trials Related to Priscoline (Tolazoline)
Pelvic Angiography in Non-Responders to Phosphodiesterase-5 Inhibitors (PANPI) [Completed]
The specific aim of this pilot study is to describe the angiographic prevalence and pattern
of internal pudendal artery (and associated inflow vessel) atherosclerosis in patients with
erectile dysfunction who are non-responsive to PDE-5 inhibitors (i. e., Viagra) who are
referred for clinically-indicated cardiac catheterization.